Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
In medical journals/research articles
Expanding Access to HIV Viral Load Testing: A Systematic Review of RNA Stability in EDTA Tubes and PPT beyond Current Time and Temperature Thresholds
HIV viral load (VL) testing is the gold standard for antiretroviral treatment monitoring, but many barriers exist to VL testing in resource-limited settings, including storage and transport limitations for whole blood and plasma. Data from various studies indicate that HIV RNA is stable beyond current recommendations. We conducted a systematic review to assess stability data of HIV RNA in whole blood and plasma across times and temperatures.
Last updated 2 December 2014
Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review
SUMMARY. The entry of new all-oral direct acting antiviral therapy for hepatitis C provides an opportunity to scale up HCV care in low- and middle-income countries. In HIV, use of dried blood spots (DBS) has facilitated the diagnosis and management of HIV in resource-poor settings. DBS may be used in a similar way to facilitate diagnosis and management of HCV.
Objectives Further scale-up of antiretroviral therapy (ART) to those in need while supporting the growing patient cohort on ART requires continuous adaptation of healthcare delivery models. We describe several approaches to manage stable patients on ART developed by Médecins Sans Frontières together with Ministries of Health in four countries in sub-Saharan Africa. Methods
Last updated 19 June 2014
Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating hepatitis C
Introduction: The current pipeline of promising oral hepatitis C drugs could lead to a revolution in treatment for this disease in both developed and developing countries. At present, the recommended treatment is pegylated interferon alpha (in combination with ribavirin). However, the limited availability and high cost of this medicine is a major barrier to expanding access to treatment in developing countries.
Last updated 7 February 2014
Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx Abstract:
Last updated 14 June 2013
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis
Introduction: Since 2002, the WHO has recommended either nevirapine (NVP) or efavirenz (EFV) as part of first-line antiretroviral therapy. These two drugs are known to have differing toxicity profiles, but the risk of these toxicities overall is not well established.
Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis
BACKGROUND: Scaling up treatment for multi-drug-resistant tuberculosis is a global health priority. However, current treatment regimens are long and associated with side effects, and default rates are consequently high. This systematic review aimed to identify strategies for reducing treatment default.
Last updated 23 February 2013
MSF submission for the inclusion of peginterferon alfa-2a and -2b in the WHO Essential Medicines List
Summary statement of the proposal for inclusion Inclusion of the injectable formulation of peginterferon alfa-2a and -2b is proposed for the treatment of hepatitis C among adults. The principal reasons for requesting this inclusion are as follows: 1. There is significant burden of hepatitis C disease among adults living in resource-limited settings.
Last updated 8 January 2013
After a major upsurge in the 1990s, HAT is now under control in most endemic regions. To prevent resurgence from re-occurring, which we know will happen if control efforts are relaxed, the continuation of control activities is crucial. In the DRC the knowledge, expertise and capacity are in place; continued funding of the national HAT control programme would allow for these to be utilized and the epidemiological situation to be kept under control.
Last updated 17 December 2012
Introduction: Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. Between 700,000 and 1.2 million cases of cutaneous leishmaniasis and between 200,000 and 400,000 cases of visceral leishmaniasis (VL), which is fatal if left untreated, occur annually worldwide. Liposomal amphotericin B (LAMB), alone or in combination with other drugs, has been extensively studied as VL treatment, but data on routine field use are limited, and several challenges to patients’ access to this life-saving drug remain.
Last updated 17 December 2012